There is substantial in-vitro data indicating that curcumin has antioxidant, anti-inflammatory, and anti-amyloid activity. In addition, studies in animal models of Alzheimer’s disease (AD) indicate a direct effect of curcumin in decreasing the amyloid pathology of AD. As the widespread use of curcumin as a food additive and relatively small short-term studies in humans suggest safety, curcumin is a promising agent in the treatment and/or prevention of AD.
Nonetheless, important information regarding curcumin bioavailability, safety and tolerability, particularly in an elderly population is lacking. We are therefore performing a study of curcumin in patients with AD to gather this information in addition to data on the effect of curcumin on biomarkers of AD pathology.
lien Pub Med:Etude complète
John M. Ringman,1* Sally A. Frautschy,2 Gregory M. Cole,2 Donna L. Masterman,3 and Jeffrey L. Cummings1,4
1 University of California, Los Angeles, Dept. of Neurology, Alzheimer’s Disease Research Center, Los Angeles, CA,
2 University of California, Los Angeles, Dept. of Medicine and the Greater Los Angeles VA Healthcare System, Geriatric Research, Education, and Clinical Center, Sepulveda, CA,
3 Amgen, Inc., Thousand Oaks, CA,
4 University of California, Los Angeles, Dept. of Psychiatry and Biobehavioral Sciences, Los Angeles, CA, USA
*Address correspondence to this author at the UCLA Dept. of Neurology, Alzheimer’s Disease Research Center, 710 Westwood Plaza, Suite 2-238, Los Angeles, CA 90095-1769, USA; Tel: (310)-206-2867; Fax: (310)-206-5287; Email: email@example.com